Young V B
Department of Internal Medicine/Infectious Diseases Division, Department of Microbiology & Immunology, University of Michigan Medical School, Ann Arbor, MI, USA.
Clin Microbiol Infect. 2016 Nov;22(11):905-909. doi: 10.1016/j.cmi.2016.09.001. Epub 2016 Sep 10.
The growing appreciation of the potential role of indigenous microbiota in disease has resulted in a concomitant interest in manipulating the microbiome for therapeutic effect. The most successful example of microbiota manipulation for treatment of a disease is in recurrent infection with the bacterial pathogen Clostridium difficile.
This review provides historic perspectives on development of microbiota transplantation and reviews evidence for its use in recurrent C. difficile infection.
A PubMed search of the terms ([fecal transplant OR fecal transplantation] AND difficile) to 9 June 2016 yielded 415 articles.
Recent work has pointed to potential mechanisms by which microbiota restoration in the form of faecal transplantation has been efficacious. This includes studies of microorganisms associated with successful faecal transplantation in human and animal studies and a focus on bacterial bile acid metabolism as a mechanism that mediates colonization resistance against the pathogen. The potential use of microbiota manipulation for other diseases such as inflammatory bowel diseases and metabolic disorders will be discussed. The case will be made that the lessons learned from treatment of recurrent C. difficile infection may not necessarily translate to use of faecal transplantation or other methods to alter the microbiome for the treatment of other diseases.
A key conclusion that can be drawn is that understanding of the precise role of the microbiota in the pathogenesis of a specific disease is necessary prior to determining if microbiota manipulation represents a novel treatment therapy.
对本土微生物群在疾病中潜在作用的认识不断增加,相应地人们也对通过操纵微生物组来产生治疗效果产生了兴趣。微生物群操纵治疗疾病最成功的例子是用于治疗细菌性病原体艰难梭菌的复发性感染。
本综述提供了微生物群移植发展的历史观点,并综述了其用于复发性艰难梭菌感染的证据。
截至2016年6月9日,在PubMed上搜索关键词([粪便移植或粪菌移植]和艰难梭菌),共获得415篇文章。
最近的研究指出了粪菌移植形式的微生物群恢复有效的潜在机制。这包括在人类和动物研究中对与成功粪菌移植相关的微生物的研究,以及将重点放在细菌胆汁酸代谢作为介导对病原体定植抗性的一种机制上。还将讨论微生物群操纵在其他疾病如炎症性肠病和代谢紊乱中的潜在应用。有观点认为,从复发性艰难梭菌感染治疗中吸取的经验教训不一定能转化为使用粪菌移植或其他方法来改变微生物组以治疗其他疾病。
可以得出的一个关键结论是,在确定微生物群操纵是否代表一种新的治疗方法之前,有必要了解微生物群在特定疾病发病机制中的精确作用。